PMID- 18001701
OWN - NLM
STAT- MEDLINE
DCOM- 20080327
LR  - 20131121
IS  - 0009-8981 (Print)
IS  - 0009-8981 (Linking)
VI  - 388
IP  - 1-2
DP  - 2008 Feb
TI  - In vivo platelet activation is responsible for enhanced vascular endothelial 
      growth factor levels in hypertensive patients.
PG  - 33-7
AB  - BACKGROUND: Essential hypertension may be a consequence of an abnormal regulation 
      of vascular endothelial growth factor (VEGF). In vivo activation of platelets 
      does result in the release of VEGF. Thus, we investigated whether VEGF production 
      in hypertensive patients is related to in vivo platelet activation, and whether 
      it may be modified by aspirin treatment. METHODS: Plasma VEGF, soluble 
      (s)P-selectin and thrombin-anti-thrombin complex (TATc) were analyzed in 80 
      patients with therapeutically controlled essential hypertension and 40 age and 
      sex-matched healthy normotensive controls. The effects of a 6-month treatment 
      with aspirin 100 mg/day on VEGF levels of 20 hypertensive patients were also 
      studied. RESULTS: Plasma VEGF (p<0.0001), sP-selectin (p=0.01) and TATc (p=0.02) 
      levels were higher in hypertensives compared to controls. Multivariate analysis 
      including age, sex, risk factors, cardiovascular disease, anti-hypertensive 
      treatment, sP-selectin and TATc showed that only sP-selectin was an independent 
      predictor of VEGF (beta=0.40, p<0.03). Aspirin treated hypertensives showed a 
      significant reduction of sP-selectin (-26%, p<0.01) and VEGF (-33%, p<0.01) 
      levels. Moreover, the reduction of plasma VEGF levels directly correlated with 
      that of sP-selectin (Rho=0.46, p=0.04). CONCLUSIONS: In vivo activation of 
      platelets in hypertensive patients is responsible for enhanced circulating VEGF 
      levels, which are significantly lowered by aspirin treatment.
FAU - Ferroni, Patrizia
AU  - Ferroni P
AD  - Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele, 
      Via della Pisana 235, Rome, Italy. patrizia.ferroni@sanraffaele.it
FAU - Martini, Francesca
AU  - Martini F
FAU - D'Alessandro, Roberta
AU  - D'Alessandro R
FAU - Magnapera, Agesilao
AU  - Magnapera A
FAU - Raparelli, Valeria
AU  - Raparelli V
FAU - Scarno, Antongiulio
AU  - Scarno A
FAU - Davi, Giovanni
AU  - Davi G
FAU - Basili, Stefania
AU  - Basili S
FAU - Guadagni, Fiorella
AU  - Guadagni F
LA  - eng
PT  - Journal Article
DEP - 20071009
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (P-Selectin)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology
MH  - Female
MH  - Humans
MH  - Hypertension/*blood
MH  - Male
MH  - P-Selectin/blood
MH  - *Platelet Activation/drug effects
MH  - Solubility
MH  - Vascular Endothelial Growth Factor A/*blood
EDAT- 2007/11/16 09:00
MHDA- 2008/03/28 09:00
CRDT- 2007/11/16 09:00
PHST- 2007/09/04 00:00 [received]
PHST- 2007/09/28 00:00 [revised]
PHST- 2007/09/28 00:00 [accepted]
PHST- 2007/11/16 09:00 [pubmed]
PHST- 2008/03/28 09:00 [medline]
PHST- 2007/11/16 09:00 [entrez]
AID - S0009-8981(07)00493-7 [pii]
AID - 10.1016/j.cca.2007.09.026 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2008 Feb;388(1-2):33-7. doi: 10.1016/j.cca.2007.09.026. Epub 2007 
      Oct 9.